Spectrem: Guselkumab Skin Clearance and Patient-Reported Outcome Results across Skin and Joint Symptoms through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis with at Least One Moderate High-Impact Site Involved
Recommended Citation
Stein Gold L, Papp KA, Langley RG, Strober B, Armstrong AW, Bissonnette R, Gottlieb AB, Krueger JG, Merola JF, Alkousakis T, Lebwohl MG. Spectrem: Guselkumab Skin Clearance and Patient-Reported Outcome Results across Skin and Joint Symptoms through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis with at Least One Moderate High-Impact Site Involved. J Am Acad Dermatol 2026; 95(1):AB411.
Document Type
Conference Proceeding
Publication Date
7-1-2026
Publication Title
J Am Acad Dermatol
Keywords
Dermatology
Abstract
Introduction: The phase 3b SPECTREM study evaluated guselkumab efficacy/safety in participants with low body surface area (BSA; 2-15%), moderate (Investigator’s Global Assessment [IGA]=3) plaque psoriasis involving ≥1 high-impact site (scalp/face/intertriginous/genital). At Week (W)16, significant improvements in skin clearance and patient-reported outcomes (PROs) were observed with guselkumab vs placebo. Here we report efficacy through W48. Methods: Participants were randomized 2:1 to receive guselkumab 100mg (W0/W4, then every 8 weeks) or placebo (W0/W4/W12; W16 placebo-guselkumab crossover). Skin clearance (IGA0/1; Psoriasis Area and Severity Index [PASI]90; mean percent improvements from baseline in BSA&PASI) and PROs (Dermatology Quality Life Index [DLQI]0/1 [no effect on quality-of-life]; mean changes from baseline in Psoriasis Symptoms and Signs Diary [PSSD] itch [clinically meaningful improvement: ≥4-point decrease]; Psoriatic Arthritis Impact of Disease-12 [PsAID-12; minimal clinically important improvement: ≥3-point decrease] among participants with rheumatologist-confirmed psoriatic arthritis [PsA] or Psoriasis Epidemiology Screening Tool≥3 at screening) were evaluated using non-responder imputation methods. Results: Baseline characteristics were balanced between guselkumab-randomized (N=225) and placebo-guselkumab (N=113) participants. At W48 in both groups, ≥80% of participants achieved IGA0/1, ∼70% achieved PASI90, and mean percent BSA&PASI improvements were >85%. Both groups achieved meaningful improvements in PROs; at W48, >60% achieved DLQI0/1, mean PSSD itch improved/decreased by ≥4.5-points, and mean PsAID-12 decreased by >3-points. No new safety signals were identified through the safety follow-up period (W52). Conclusions: Consistent improvements across clinician-evaluated skin clearance and skin/joint PRO measures, including meaningful reductions in PsA symptoms, substantiate guselkumab’s effectiveness in patients with low BSA, moderate psoriasis with high-impact site involvement.
Volume
95
Issue
1
First Page
AB411
